Our group have an approach driving projects to personalize cancer medicine and decipher tumor information into actionable knowledge.
One research focus relates to the interaction between cancer cells and their microenvironment, and how the tumor can circumvent the immunosurveillance, called immune editing, and the new line of immunotherapies directed against them, e.g. check-point inhibitors.
This website uses cookies which are stored in your browser. Some cookies are necessary for the page to work properly and others are selectable. You choose which ones you want to allow.